Nashaat T Nashed

Array ( [id] => 17035128 [patent_doc_number] => 20210252086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => ONCOLYTIC VIRUS PLATFORM TO TREAT HEMATOLOGICAL CANCER [patent_app_type] => utility [patent_app_number] => 17/274051 [patent_app_country] => US [patent_app_date] => 2019-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -116 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17274051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17142015 [patent_doc_number] => 20210310027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => METHODS AND COMPOSITIONS FOR PRODUCING A VIRUS [patent_app_type] => utility [patent_app_number] => 17/269450 [patent_app_country] => US [patent_app_date] => 2019-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170737 [patent_doc_number] => 20210324407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => SELF-INACTIVATING TRANSPOSASE PLASMIDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/271814 [patent_app_country] => US [patent_app_date] => 2019-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15793 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17271814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003642 [patent_doc_number] => 20220362408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => OPTIMIZED PROMOTER SEQUENCES, INTRON-FREE EXPRESSION CONSTRUCTS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/250712 [patent_app_country] => US [patent_app_date] => 2019-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34472 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -96 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17250712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760040 [patent_doc_number] => 20220233652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => Pharmaceutical Compositions Comprising Integration-Promoting Peptides [patent_app_type] => utility [patent_app_number] => 17/270262 [patent_app_country] => US [patent_app_date] => 2019-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20670 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270262 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16901173 [patent_doc_number] => 20210180089 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => NANOPARTICLES FOR TRANSFECTION [patent_app_type] => utility [patent_app_number] => 17/267166 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17156128 [patent_doc_number] => 20210317179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-14 [patent_title] => PRECISELY ENGINEERED STEALTHY MESSENGER RNAS AND OTHER POLYNUCLEOTIDES [patent_app_type] => utility [patent_app_number] => 17/267299 [patent_app_country] => US [patent_app_date] => 2019-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885787 [patent_doc_number] => 20210171982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => IMPROVED CLINICAL PARAMETERS BY EXPRESSION OF FACTOR VIII [patent_app_type] => utility [patent_app_number] => 17/265750 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13383 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17112111 [patent_doc_number] => 20210292708 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => CELL PRODUCTION METHOD [patent_app_type] => utility [patent_app_number] => 17/265364 [patent_app_country] => US [patent_app_date] => 2019-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17265364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067557 [patent_doc_number] => 20210269772 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => COMPOSITIONS AND METHODS RELATED TO APTAMER-BASED REVERSIBLE CELL SELECTION [patent_app_type] => utility [patent_app_number] => 17/260111 [patent_app_country] => US [patent_app_date] => 2019-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260111 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082354 [patent_doc_number] => 20210277360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => CELL LINKERS FOR HETEROTYPIC CELL SPHEROIDS [patent_app_type] => utility [patent_app_number] => 17/260365 [patent_app_country] => US [patent_app_date] => 2019-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6033 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16990319 [patent_doc_number] => 20210228739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => RAAV VECTORS ENCODING OF LYSOSOMAL BETA-GALACTOSIDASE (GLB1) AND CATHEPSIN A [patent_app_type] => utility [patent_app_number] => 17/054791 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17067610 [patent_doc_number] => 20210269825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-02 [patent_title] => COMPOSITIONS AND METHODS FOR REDUCING SPLICEOPATHY AND TREATING RNA DOMINANCE DISORDERS [patent_app_type] => utility [patent_app_number] => 17/054474 [patent_app_country] => US [patent_app_date] => 2019-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054474 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17548468 [patent_doc_number] => 20220119809 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => CRISPR-cas9 SYSTEM AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/054008 [patent_app_country] => US [patent_app_date] => 2019-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17054008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036694 [patent_doc_number] => 20210253652 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => EXPRESSION OF HUMAN FOXP3 IN GENE EDITED T CELLS [patent_app_type] => utility [patent_app_number] => 16/981213 [patent_app_country] => US [patent_app_date] => 2019-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 77419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16981213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17082072 [patent_doc_number] => 20210277078 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-09 [patent_title] => FIBER ASSEMBLY AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/962828 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8023 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962828 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17126520 [patent_doc_number] => 20210301288 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-30 [patent_title] => NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS [patent_app_type] => utility [patent_app_number] => 17/260791 [patent_app_country] => US [patent_app_date] => 2018-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260791 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228936 [patent_doc_number] => 20210355492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => CARGO LOADED EXTRACELLULAR VESICLES [patent_app_type] => utility [patent_app_number] => 17/278275 [patent_app_country] => US [patent_app_date] => 2018-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23478 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278275 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17112196 [patent_doc_number] => 20210292793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => COMPOSITIONS AND METHODS FOR GENERATING PHYSIOLOGICAL X CHROMOSOME INACTIVATION [patent_app_type] => utility [patent_app_number] => 17/260283 [patent_app_country] => US [patent_app_date] => 2018-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15176 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17260283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931859 [patent_doc_number] => 20200157563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => METHODS OF PRODUCING HUMAN CANCER CELL MODELS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/631916 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 90723 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -77 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16631916 [rel_patent_id] =>[rel_patent_doc_number] =>)